aclidinium vs omalizumab
Side-by-side comparison of aclidinium and omalizumab Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Tudorza Pressair
Xolair
Duaklir Pressair is a combination medicine used to help people with COPD breathe better. It contains two medicines that open up the airways in your lungs.
Xolair is a medicine that can help with asthma, nasal polyps, food allergies, and chronic hives. It works by blocking a substance in your body called IgE.
Duaklir Pressair is used to treat chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that makes it hard to breathe. This medicine helps to open the airways and make it easier to breathe for people with COPD.
Xolair can treat moderate to severe asthma in people 6 years and older who have allergies. It can also treat chronic rhinosinusitis with nasal polyps in adults 18 years and older when nasal sprays don't work well enough. Xolair can also help reduce allergic reactions to food in people 1 year and older, but you still need to avoid the foods you are allergic to. Xolair can also treat chronic hives in people 12 years and older when antihistamines don't work.
Duaklir Pressair contains two medicines that work in different ways. One medicine relaxes the muscles around your airways, opening them up. The other medicine prevents the muscles from tightening.
Xolair is a special type of medicine called an anti-IgE monoclonal antibody. It blocks immunoglobulin E (IgE) in your body. IgE is a substance that causes allergic reactions and inflammation.
- • Upper respiratory infection
- • Headache
- • Back pain
- • Joint pain
- • General pain
- • Leg pain
- • Tiredness
- • Dizziness
- Difficulty breathing 1,869
- Inhaler not working correctly 1,281
- Skipped a dose of medicine 1,017
- Asthma 814
- Chronic obstructive pulmonary disease (COPD) 764
- Asthma 11,602
- Hives 10,326
- No side effect 10,204
- Using the medicine for something it's not approved for 9,929
- Difficulty breathing 9,876
LABAs, such as formoterol fumarate, one of the active ingredients in DUAKLIR PRESSAIR, increase the risk of asthma-related death. Duaklir Pressair is not for asthma. Do not use Duaklir Pressair if you are allergic to milk proteins or any of the ingredients in it. Tell your doctor if you have heart problems, glaucoma, trouble urinating, diabetes, or seizures.
Xolair can cause a severe allergic reaction called anaphylaxis, even after the first dose or after you have been taking it for a year or more. This reaction can cause trouble breathing, low blood pressure, fainting, hives, and swelling of the throat or tongue. Because of this risk, your doctor should give you Xolair in a healthcare setting where they can treat anaphylaxis. Watch for signs of anaphylaxis after each Xolair injection and seek immediate medical care if symptoms occur.
It is not known if Duaklir Pressair will harm an unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if this medicine passes into breast milk. Talk to your doctor about the best way to feed your baby if you are taking Duaklir Pressair.
Tell your doctor if you are pregnant or plan to become pregnant. It is not known how Xolair will affect your unborn baby, but poorly controlled asthma during pregnancy can be risky. Talk to your doctor about the risks and benefits of taking Xolair during pregnancy.
Also Compare — Nearby Drugs
Compare aclidinium with
How to Read This aclidinium vs omalizumab Comparison
aclidinium is classified in the Long-Acting Muscarinic Antagonist (LAMA) drug class, while omalizumab sits within the Anti-IgE Monoclonal Antibody class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, aclidinium has 5,745 submissions while omalizumab has 51,937. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between aclidinium and omalizumab — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.